{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:44:45Z","timestamp":1790729085016,"version":"4.1.0"},"reference-count":130,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    Evidence is accumulating that components of the\n                    <jats:italic>Cannabis sativa<\/jats:italic>\n                    plant may have therapeutic potential in treating psychiatric disorders. Medicinal cannabis (MC) products are legally available for prescription in Australia, primarily through the Therapeutic Goods Administration (TGA) Special Access Scheme B (SAS-B). Here we investigated recent prescribing practices for psychiatric indications under SAS-B by Australian doctors.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    The dataset, obtained from the TGA, included information on MC applications made by doctors through the SAS-B process between 1st November 2016 and 30th September 2022 inclusive. Details included the primary conditions treated, patient demographics, prescriber location, product type (e.g., oil, flower or capsule) and the general cannabinoid content of products. The conditions treated were categorized according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, text revision (DSM-5-TR). Trends in prescribing for conditions over time were analyzed via polynomial regression, and relationships between categorical variables determined via correspondence analyses.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Approximately 300,000 SAS-B approvals to prescribe MC had been issued in the time period under investigation. This included approvals for 38 different DSM-5-TR defined psychiatric conditions (33.9% of total approvals). The majority of approvals were for anxiety disorders (66.7% of psychiatry-related prescribing), sleep-wake disorders (18.2%), trauma- and stressor-related disorders (5.8%), and neurodevelopmental disorders (4.4%). Oil products were most prescribed (53.0%), followed by flower (31.2%) and other inhaled products (12.4%). CBD-dominant products comprised around 20% of total prescribing and were particularly prevalent in the treatment of autism spectrum disorder. The largest proportion of approvals was for patients aged 25\u201339\u00a0years (46.2% of approvals). Recent dramatic increases in prescribing for attention deficit hyperactivity disorder were identified.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    A significant proportion of MC prescribing in Australia is for psychiatry-related indications. This prescribing often appears somewhat \u201cexperimental\u201d, given it involves conditions (e.g., ADHD, depression) for which definitive clinical evidence of MC efficacy is lacking. The high prevalence of THC-containing products being prescribed is of possible concern given the psychiatric problems associated with this drug. Evidence-based clinical guidance around the use of MC products in psychiatry is lacking and would clearly be of benefit to prescribers.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2023.1142680","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:27:11Z","timestamp":1686011231000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing"],"prefix":"10.3389","volume":"14","author":[{"given":"Elizabeth A.","family":"Cairns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Bedoya-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara L.","family":"Macphail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adith","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhys","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perminder S.","family":"Sachdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain S.","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1176\/appi.ajp.162.3.458","article-title":"Jacques joseph Moreau (1804-1884)","volume":"162","author":"Abel","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00213-019-05442-6","article-title":"Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis","volume":"237","author":"Appiah-Kusi","year":"2020","journal-title":"Psychopharmacol. Berl."},{"key":"B3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13229-021-00420-2","article-title":"Cannabinoid treatment for autism: A proof-of-concept randomized trial","volume":"12","author":"Aran","year":"2021","journal-title":"Mol. Autism"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s00213-019-05246-8","article-title":"Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition","volume":"236","author":"Arkell","year":"2019","journal-title":"Psychopharmacol. Berl."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1136\/bmj.325.7374.1212","article-title":"Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study","volume":"325","author":"Arseneault","year":"2002","journal-title":"BMJ"},{"key":"B6","unstructured":"Population: Census\n            Australian Bureau of Statistics\n          2022"},{"key":"B7","unstructured":"National drug strategy household survey 2019\n            Australian Institute of Health and Welfare\n          2020"},{"key":"B8","unstructured":"Prevalence and impact of mental illness\n            Australian Institute of Health and Welfare\n          2022"},{"key":"B9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jpsychires.2020.07.030","article-title":"Efficacy and acceptability of cannabinoids for anxiety disorders in adults: A systematic review & meta-analysis","volume":"129","author":"Bahji","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jad.2017.02.016","article-title":"Patterns of marijuana use among psychiatry patients with depression and its impact on recovery","volume":"213","author":"Bahorik","year":"2017","journal-title":"J. Affect Disord."},{"key":"B11","unstructured":"MuMIn: Multi-Model inference\n            Barto\u0144K.\n          2020"},{"key":"B12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11096-022-01519-z","article-title":"A cross-sectional survey exploring the knowledge, experiences and attitudes of Australian pharmacists toward medicinal cannabis","volume":"45","author":"Bawa","year":"2022","journal-title":"Int. J. Clin. Pharm."},{"key":"B13","doi-asserted-by":"publisher","first-page":"otaa045","DOI":"10.1093\/crocol\/otaa045","article-title":"Attitudes and knowledge of Australian gastroenterologists around the use of medicinal cannabis for inflammatory bowel disease","volume":"360","author":"Benson","year":"2020","journal-title":"Crohn's Colitis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"586","DOI":"10.31128\/AJGP-04-21-5936","article-title":"Medicinal cannabis for the treatment of anxiety disorders","volume":"51","author":"Berger","year":"","journal-title":"Aust. J. Gen. Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"21m14130","DOI":"10.4088\/JCP.21m14130","article-title":"Cannabidiol for treatment-resistant anxiety disorders in young people: An open-label trial","volume":"83","author":"Berger","year":"","journal-title":"J. Clin. Psychiatry"},{"key":"B17","first-page":"8","article-title":"Treating depression with cannabinoids","volume":"3","author":"Blaas","year":"2008","journal-title":"Cannabinoids"},{"key":"B18","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","article-title":"Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: A systematic review and meta-analysis","volume":"6","author":"Black","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","article-title":"The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial","volume":"235","author":"Boggs","year":"2018","journal-title":"Psychopharmacol. Berl."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00213-021-06043-y","article-title":"Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder","volume":"239","author":"Bolsoni","year":"2022","journal-title":"Psychopharmacol. Berl."},{"key":"B21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuro.2019.08.002","article-title":"Cannabidiol (CBD) use in psychiatric disorders: A systematic review","volume":"74","author":"Bonaccorso","year":"2019","journal-title":"Neurotoxicology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ajad.12963","article-title":"Cannabis and cannabinoids in mood and anxiety disorders: Impact on illness onset and course, and assessment of therapeutic potential","volume":"29","author":"Botsford","year":"2020","journal-title":"Am. J. Addict."},{"key":"B23","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1177\/0004867417721018","article-title":"Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure","volume":"51","author":"Brett","year":"2017","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"B24","volume-title":"A practical information-theoretic approach","author":"Burnham","year":"2002"},{"key":"B25","doi-asserted-by":"publisher","first-page":"E927-E928","DOI":"10.1503\/cmaj.170427","article-title":"Why support a separate medical access framework for cannabis?","volume":"189","author":"Cairns","year":"2017","journal-title":"CMAJ"},{"key":"B26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/JCP.0000000000000180","article-title":"Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: A retrospective evaluation","volume":"34","author":"Cameron","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"417S-427S","DOI":"10.1002\/j.1552-4604.1981.tb02622.x","article-title":"Hypnotic and antiepileptic effects of cannabidiol","volume":"21","author":"Carlini","year":"1981","journal-title":"J. Clin. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3389\/fpsyg.2020.00833","article-title":"Unraveling the intoxicating and therapeutic effects of cannabis ingredients on psychosis and cognition","volume":"11","author":"Colizzi","year":"2020","journal-title":"Front. Psychol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.euroneuro.2017.05.005","article-title":"Cannabinoids in attention-deficit\/hyperactivity disorder: A randomised-controlled trial","volume":"27","author":"Cooper","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/BF00437513","article-title":"(- Delta 9 THC as an hypnotic. An experimental study of three dose levels","volume":"33","author":"Cousens","year":"1973","journal-title":"Psychopharmacologia"},{"key":"B32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report","volume":"25","author":"Crippa","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/15622975.2022.2038797","article-title":"Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis","volume":"23","author":"D'Souza","year":"2022","journal-title":"World J. Biol. Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s43856-022-00202-8","article-title":"Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: Open-label data from a two-stage, phase 2 clinical trial","volume":"2","author":"Dahlgren","year":"2022","journal-title":"Commun. Med. (Lond)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/YCO.0b013e3282f51266","article-title":"The effect of cannabis on the brain: Can it cause brain anomalies that lead to increased risk for schizophrenia?","volume":"21","author":"DeLisi","year":"2008","journal-title":"Curr. Opin. Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the lennox-gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S2215-0366(19)30048-3","article-title":"The contribution of cannabis use to variation in the incidence of psychotic disorder across europe (EU-GEI): A multicentre case-control study","volume":"6","author":"Di Forti","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"B39","article-title":"Access medical cannabis with project Twenty21","author":"Drug Science","year":"2022"},{"key":"B40","doi-asserted-by":"publisher","first-page":"352","DOI":"10.31128\/AJGP-01-21-5809","article-title":"Potential therapeutic uses of cannabinoids to treat behavioural problems in children and adolescents with developmental disorders","volume":"50","author":"Efron","year":"2021","journal-title":"Aust. J. Gen. Pract."},{"key":"B41","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1089\/acm.2018.0437","article-title":"Cannabidiol in the treatment of post-traumatic stress disorder: A case series","volume":"25","author":"Elms","year":"2019","journal-title":"J. Altern. Complement. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41386-022-01478-z","article-title":"Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios","volume":"48","author":"Englund","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"103381","DOI":"10.1016\/j.drugpo.2021.103381","article-title":"Lower-risk cannabis use guidelines (lrcug) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update","volume":"99","author":"Fischer","year":"2022","journal-title":"Int. J. Drug Policy"},{"key":"B44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/cch.12909","article-title":"Medicinal cannabis in children and adolescents with autism spectrum disorder: A scoping review","volume":"48","author":"Fletcher","year":"2021","journal-title":"Child. Care Health Dev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1515\/jbcpp-2020-0279","article-title":"Use of cannabinoids for the treatment of patients with post-traumatic stress disorder","volume":"33","author":"Forsythe","year":"2021","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1755-5949.2008.00071.x","article-title":"The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD)","volume":"15","author":"Fraser","year":"2009","journal-title":"CNS Neurosci. Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.neubiorev.2019.09.036","article-title":"How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review","volume":"107","author":"Freeman","year":"2019","journal-title":"Neurosci. Biobehav Rev."},{"key":"B48","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/schbul\/sbu098","article-title":"How cannabis causes paranoia: Using the intravenous administration of \u22069-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia","volume":"41","author":"Freeman","year":"2015","journal-title":"Schizophr. Bull."},{"key":"B49","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","article-title":"Cannabidiol for the treatment of cannabis use disorder: A phase 2a, double-blind, placebo-controlled, randomised, adaptive bayesian trial","volume":"7","author":"Freeman","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e2013802","DOI":"10.1001\/jamanetworkopen.2020.13802","article-title":"Association of depression with past-month cannabis use among US adults aged 20 to 59 Years, 2005 to 2016","volume":"3","author":"Gorfinkel","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"B52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/(SICI)1522-7162","article-title":"Do patients use marijuana as an antidepressant?","volume":"4","author":"Gruber","year":"1996","journal-title":"Depression"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpopen20X101010","article-title":"Cannabidiol prescription in clinical practice: An audit on the first 400 patients in New Zealand","volume":"4","author":"Gulbransen","year":"2020","journal-title":"BJGP Open"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1177\/0269881118799954","article-title":"Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats","volume":"32","author":"Hay","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1038\/525S14a","article-title":"Perspective: Be clear about the real risks","volume":"525","author":"Hill","year":"2015","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/15504263.2019.1652380","article-title":"The effectiveness of cannabinoids in the treatment of posttraumatic stress disorder (PTSD): A systematic review","volume":"16","author":"Hindocha","year":"2020","journal-title":"J. Dual Diagn"},{"key":"B57","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00406-019-00984-4","article-title":"How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review","volume":"269","author":"Hoch","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/add.14845","article-title":"Major depressive disorder working group of the psychiatric genomics cannabis use, depression and self-harm: Phenotypic and genetic relationships","volume":"115","author":"Hodgson","year":"2020","journal-title":"Addiction"},{"key":"B59","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.drugalcdep.2012.06.002","article-title":"Cannabis and depression: An integrative data analysis of four australasian cohorts","volume":"126","author":"Horwood","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"B60","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1198\/000313006x118430","article-title":"A lego system for conditional inference","volume":"60","author":"Hothorn","year":"2006","journal-title":"Am. Statistician"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1007\/s00213-022-06248-9","article-title":"Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis","volume":"239","author":"Hutten","year":"2022","journal-title":"Psychopharmacol. Berl."},{"key":"B62","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","article-title":"The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study","volume":"51","author":"Jetly","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e022101","DOI":"10.1136\/bmjopen-2018-022101","article-title":"Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: A cross-sectional survey","volume":"8","author":"Karanges","year":"2018","journal-title":"BMJ Open"},{"key":"B64","unstructured":"ggpubr: \u2018ggplot2\u2019 based publication ready plots. R package version 0.4.0\n            KassambaraA.\n          2020"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42238-019-0012-y","article-title":"The therapeutic role of cannabidiol in mental health: A systematic review","volume":"2","author":"Khan","year":"2020","journal-title":"J. Cannabis Res."},{"key":"B66","first-page":"1","article-title":"Cannabinoid drugs in mental health disorders","volume-title":"NeuroPsychopharmacotherapy","author":"Kloiber","year":"2021"},{"key":"B67","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results","volume":"154","author":"Laux","year":"2019","journal-title":"Epilepsy Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.chest.2022.04.151","article-title":"Cannabinoids, insomnia, and other sleep disorders","volume":"162","author":"Lavender","year":"2022","journal-title":"Chest"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"B70","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","article-title":"Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test","volume":"41","author":"Linares","year":"2019","journal-title":"Braz. J. Psychiatry"},{"key":"B71","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-022-00666-w","article-title":"Medical cannabis use in Australia: Consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20)","volume":"19","author":"Lintzeris","year":"2022","journal-title":"Harm Reduct. J."},{"key":"B72","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.addbeh.2017.01.008","article-title":"Medicinal versus recreational cannabis use: Patterns of cannabis use, alcohol use, and cued-arousal among veterans who screen positive for PTSD","volume":"68","author":"Loflin","year":"2017","journal-title":"Addict. Behav."},{"key":"B73","doi-asserted-by":"publisher","first-page":"885655","DOI":"10.3389\/fphar.2022.885655","article-title":"Medicinal cannabis prescribing in Australia: An analysis of trends over the first five years","volume":"13","author":"MacPhail","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"4966","DOI":"10.2174\/138161212802884780","article-title":"Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers","volume":"18","author":"Martin-Santos","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3389\/fpsyg.2019.02466","article-title":"Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders","volume":"10","author":"Masataka","year":"2019","journal-title":"Front. Psychol."},{"key":"B76","article-title":"Medical cannabis as a treatment for chronic combat PTSD","author":"Mashiah","year":""},{"key":"B77","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"B78","unstructured":"Recommendations and guidance on medical cannabis under prescription\n            Medical Cannabis Clinicians\u2019 Society\n          2021"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-Assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"key":"B80","volume-title":"The basic practice of statistics","author":"Moore","year":"2013"},{"key":"B81","volume-title":"The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research","author":"National Academies of Sciences, E., and Medicine","year":"2017"},{"key":"B82","unstructured":"Cannabis-based medicinal products\n            National Institute for Health and Care Excellence\n          2019"},{"key":"B83","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/01.jcp.0000125688.05091.8f","article-title":"Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults","volume":"24","author":"Nicholson","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"139","DOI":"10.31887\/DCNS.2019.21.2\/dnutt","article-title":"Psychedelic drugs-a new era in psychiatry?","volume":"21","author":"Nutt","year":"2019","journal-title":"Dialogues Clin. Neurosci."},{"key":"B85","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jad.2020.12.043","article-title":"Comorbid cannabis use disorder with major depression and generalized anxiety disorder: A systematic review with meta-analysis of nationally representative epidemiological surveys","volume":"281","author":"Onaemo","year":"2021","journal-title":"J. Affect Disord."},{"key":"B86","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/medicina55090525","article-title":"Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (PTSD): A systematic review","volume":"55","author":"Orsolini","year":"2019","journal-title":"Med. Kaunas."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41593-018-0206-1","article-title":"GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia","volume":"21","author":"Pasman","year":"2018","journal-title":"Nat. Neurosci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/dta.1377","article-title":"Mitigation of post-traumatic stress symptoms by cannabis resin: A review of the clinical and neurobiological evidence","volume":"4","author":"Passie","year":"2012","journal-title":"Drug Test. Analysis"},{"key":"B89","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fphar.2020.00063","article-title":"Cannabidiol drugs clinical trial outcomes and adverse effects","volume":"11","author":"Pauli","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/sj.npp.1301475","article-title":"Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure","volume":"33","author":"Quinn","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"B91","article-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2022","journal-title":"R foundation for statistical computing"},{"key":"B92","doi-asserted-by":"publisher","first-page":"679","DOI":"10.5664\/jcsm.7070","article-title":"Medical cannabis and the treatment of obstructive sleep apnea: An American Academy of sleep medicine position statement","volume":"14","author":"Ramar","year":"2018","journal-title":"J. Clin. Sleep. Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3934\/Neuroscience.2021022","article-title":"Cannabis in the management of PTSD: A systematic review","volume":"8","author":"Rehman","year":"2021","journal-title":"AIMS Neurosci."},{"key":"B94","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40261-014-0212-3","article-title":"Preliminary, open-label, pilot study of add-on oral \u03949-tetrahydrocannabinol in chronic post-traumatic stress disorder","volume":"34","author":"Roitman","year":"2014","journal-title":"Clin. Drug Investig."},{"key":"B95","doi-asserted-by":"publisher","first-page":"18r12475","DOI":"10.4088\/JCP.18r12475","article-title":"Oral ketamine for depression: A systematic review","volume":"80","author":"Rosenblat","year":"2019","journal-title":"J. Clin. Psychiatry"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00213-021-05855-2","article-title":"Developing a real-world evidence base for prescribed cannabis in the United Kingdom: Preliminary findings from project Twenty21","volume":"239","author":"Sakal","year":"2022","journal-title":"Psychopharmacol. Berl."},{"key":"B97","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12888-019-2409-8","article-title":"Medicinal cannabis for psychiatric disorders: A clinically-focused systematic review","volume":"20","author":"Sarris","year":"2020","journal-title":"BMC Psychiatry"},{"key":"B98","doi-asserted-by":"publisher","first-page":"271","DOI":"10.31887\/DCNS.2020.22.3\/pfadda","article-title":"Cannabinoids and their therapeutic applications in mental disorders","volume":"22","author":"Scherma","year":"2020","journal-title":"Dialogues Clin. Neurosci."},{"key":"B99","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7812\/TPP\/18-041","article-title":"Cannabidiol in anxiety and sleep: A large case series","volume":"23","author":"Shannon","year":"2019","journal-title":"Perm. J."},{"key":"B100","doi-asserted-by":"publisher","first-page":"16","DOI":"10.7812\/TPP\/16-005","article-title":"Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: A case report","volume":"20","author":"Shannon","year":"2016","journal-title":"Perm. J."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00213-021-05823-w","article-title":"Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: A randomized crossover study","volume":"238","author":"Spinella","year":"2021","journal-title":"Psychopharmacol. Berl."},{"key":"B102","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1176\/appi.ps.202000189","article-title":"Evidence for use of cannabinoids in mood disorders, anxiety disorders, and PTSD: A systematic review","volume":"72","author":"Stanciu","year":"2021","journal-title":"Psychiatr. Serv."},{"key":"B103","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3390\/life11030214","article-title":"Endocannabinoid system as therapeutic target of PTSD: A systematic review","volume":"11","author":"Steardo","year":"2021","journal-title":"Life (Basel)"},{"key":"B104","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/0004867412466595","article-title":"Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011","volume":"47","author":"Stephenson","year":"2013","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"B105","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1037\/pro0000269","article-title":"Working with clients who self-medicate using cannabis: Ethical and clinical considerations for psychologists","volume":"51","author":"Stuart-Maver","year":"2020","journal-title":"Prof. Psychol. Res. Pract."},{"key":"B106","doi-asserted-by":"publisher","first-page":"A3","DOI":"10.1093\/sleepadvances\/zpac029.005","article-title":"O006 acute effects of combined cannabidiol (CBD) and \u22069-tetrahydrocannabinol (THC) in insomnia disorder: A randomised, placebo-controlled trial using high-density eeg","volume":"3","author":"Suraev","year":"2022","journal-title":"Sleep. Adv."},{"key":"B107","doi-asserted-by":"publisher","first-page":"101339","DOI":"10.1016\/j.smrv.2020.101339","article-title":"Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies","volume":"53","author":"Suraev","year":"2020","journal-title":"Sleep. Med. Rev."},{"key":"B108","doi-asserted-by":"publisher","first-page":"106933","DOI":"10.1016\/j.cct.2022.106933","article-title":"Use of Cannabidiol (CBD) oil in the treatment of PTSD: Study design and rationale for a placebo-controlled randomized clinical trial","volume":"122","author":"Telch","year":"2022","journal-title":"Contemp. Clin. Trials"},{"key":"B109","unstructured":"Medicinal cannabis - guidance documents\n            Therapeutic Goods Administration\n          2019"},{"key":"B110","unstructured":"Medicinal cannabis authorised prescriber scheme data\n            Therapeutic Goods Administration"},{"key":"B111","unstructured":"Medicinal cannabis products by active ingredients\n            Therapeutic Goods Administration"},{"key":"B112","unstructured":"padr: Quickly get datetime data ready for analysis\n            ThoenE.\n          2020"},{"key":"B113","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1080\/02791072.2017.1320734","article-title":"Psilocybin-assisted therapy: A review of a novel treatment for psychiatric disorders","volume":"49","author":"Thomas","year":"2017","journal-title":"J. Psychoact. Drugs"},{"key":"B114","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/0706743720945525","article-title":"Are there therapeutic benefits of cannabinoid products in adult mental illness?","volume":"66","author":"Tibbo","year":"2021","journal-title":"Can. J. Psychiatry"},{"key":"B115","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ejphar.2008.01.058","article-title":"Cannabis and the developing brain: Insights from behavior","volume":"585","author":"Trezza","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/acer.13964","article-title":"Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: A systematic review","volume":"43","author":"Turna","year":"2019","journal-title":"Alcohol Clin. Exp. Res."},{"key":"B117","unstructured":"Factoshiny: Perform factorial analysis from 'FactoMineR' with a shiny application\n            VaissieP.\n            MongeA.\n            HussonF.\n          2021"},{"key":"B118","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-21706-2","volume-title":"Modern applied statistics with S","author":"Venables","year":"2002"},{"key":"B119","doi-asserted-by":"publisher","first-page":"e0272241","DOI":"10.1371\/journal.pone.0272241","article-title":"A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years","volume":"17","author":"Vickery","year":"2022","journal-title":"PLoS One"},{"key":"B120","doi-asserted-by":"publisher","first-page":"zsab149","DOI":"10.1093\/sleep\/zsab149","article-title":"Treating insomnia symptoms with medicinal cannabis: A randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo","volume":"44","author":"Walsh","year":"2021","journal-title":"Sleep"},{"key":"B121","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1213\/ANE.0b013e3181c76f70","article-title":"The effects of nabilone on sleep in fibromyalgia: Results of a randomized controlled trial","volume":"110","author":"Ware","year":"2010","journal-title":"Anesth. Analg."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1523\/JNEUROSCI.2946-14.2015","article-title":"Daily marijuana use is not associated with brain morphometric measures in adolescents or adults","volume":"35","author":"Weiland","year":"2015","journal-title":"J. Neurosci."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J. Open Source Softw."},{"key":"B124","unstructured":"dplyr: a grammar of data manipulation\n            WickhamH.\n            Fran\u00e7oisR.\n            HenryL.\n            M\u00fcllerK.\n          2021"},{"key":"B125","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant graphics for data analysis","author":"Wickham","year":"2016"},{"key":"B126","unstructured":"cowplot: streamlined plot theme and plot annotations for \u2018ggplot2\u2019\n            WilkeC.\n          2020"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.4088\/JCP.14m09475","article-title":"Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder","volume":"76","author":"Wilkinson","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"B128","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000438780","article-title":"Does cannabinoid really improve sleep? Testing the sleep effects of nabilone in chronic pain patients: A placebo-controlled, randomized, pilot study","volume":"84","author":"Zalai","year":"2015","journal-title":"Psychother. Psychosom."},{"key":"B129","doi-asserted-by":"publisher","first-page":"e2254752","DOI":"10.1001\/jamanetworkopen.2022.54752","article-title":"Assessment of orally administered d9-tetrahydrocannabinol when coadministered with cannabidiol on d9-tetrahydrocannabinol pharmacokinetics and pharmacodynamics in healthy adults: A randomized clinical trial","volume":"6","author":"Zamarripa","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"B130","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/0269881108096521","article-title":"Cannabidiol was ineffective for manic episode of bipolar affective disorder","volume":"24","author":"Zuardi","year":"2010","journal-title":"J. Psychopharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1142680\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:27:31Z","timestamp":1686011251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1142680\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":130,"alternative-id":["10.3389\/fphar.2023.1142680"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1142680","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"article-number":"1142680"}}